Teva Pharm third-quarter profit tops estimates as branded drugs gain

Core Insights - Teva Pharmaceutical Industries reported a higher-than-expected rise in third-quarter profit, driven by strong sales of its trio of branded drugs for migraines, Huntington's disease, and other conditions [1] Financial Performance - The company's third-quarter profit exceeded expectations, indicating robust financial health and effective market strategies [1] Product Performance - Strong sales from three key branded drugs contributed significantly to the profit increase, showcasing the effectiveness of Teva's product portfolio in addressing specific health conditions [1]